The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
I. Sougklakos
No relevant relationships to disclose
N. K. Vardakis
No relevant relationships to disclose
E. Kampouraki
No relevant relationships to disclose
I. Kotortsi
No relevant relationships to disclose
N. E. M. Androulakis
No relevant relationships to disclose
L. Vamvakas
No relevant relationships to disclose
K. Kalbakis
No relevant relationships to disclose
D. Hatzidaki
No relevant relationships to disclose
D. Mavroudis
No relevant relationships to disclose
V. Georgoulias
No relevant relationships to disclose